Myriad Genetics, Inc. MYGN

NAS: MYGN | ISIN: US62855J1043   19/12/2025
6,550 USD (-2,24%)
(-2,24%)   19/12/2025
Grafiek Myriad Genetics, Inc. Grafiek Myriad Genetics, Inc.

Myriad Genetics, Inc. in het nieuws

23 september 2025 · Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy · Persbericht

11 juni 2024 · Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries · Persbericht

28 september 2023 · Breast Cancer Awareness Month: New Cancer Risk Survey Reveals Risk Factors Are Widely Misunderstood · Persbericht

2 maart 2023 · Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States · Persbericht

31 augustus 2022 · New Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients · Persbericht

31 augustus 2022 · Une nouvelle étude publiée dans le Clinical Cancer Research Journal met en avant l’utilisation du test EndoPredict pour éclairer les décisions thérapeutiques chez les patientes préménopausées atteintes d’un cancer du sein · Persbericht

16 augustus 2022 · Myriad Genetics Partners with Institut für Hämopathologie Hamburg and Centre Georges-Francois LeClerc to Expand Access to Genetic Testing in Europe · Persbericht

7 september 2021 · Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations · Persbericht

27 mei 2021 · IPM Launches GeneSight® Pharmacogenomics Program for Depression and Anxiety · Persbericht

2 maart 2021 · Myriad Genetics Joins Forces with Intermountain Precision Genomics for a Comprehensive Offering of Germline and Somatic Tumor Testing Services · Persbericht

Profiel Myriad Genetics, Inc.

Biotechnologie
Fabricage van farmaceutische preparaten
Gezondheidstechnologie
Productie

Website: www.myriad.com

Hoofdzetel: Salt Lake City, Utah vlag Verenigde Staten

Mijn selecties